10,238 results match your criteria Natriuretic Peptides in Congestive Heart Failure


Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.

Authors:
Johji Kato

Peptides 2020 Jun 28:170352. Epub 2020 Jun 28.

Frontier Science Research Center, University of Miyazaki Faculty of Medicine, Cardiovascular Medicine, University of Miyazaki Hospital, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. Electronic address:

The family of natriuretic peptides (NPs) discovered in mammalian tissues including cardiac atrium and brain consists of three members, namely, atrial, B- and C-type natriuretic peptides (ANP, BNP, CNP). Since the discovery, basic and clinical studies have been vigorously performed to explore the biological functions and pathophysiological roles of NPs in a wide range of diseases including hypertension and heart failure. These studies revealed that ANP and BNP are hormones secreted from the heart into the blood stream in response to pre- or after-load, counteracting blood pressure (BP) elevation and fluid retention through specific receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2020.170352DOI Listing

Increased Concentrations of bioactive Adrenomedullin subsequently to ARNi Treatment in Chronic Systolic Heart Failure.

Br J Clin Pharmacol 2020 Jun 29. Epub 2020 Jun 29.

Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

Aims: The clinically investigated rationale for neprilysin (NEP)-inhibition by ARNi-therapy is to induce elevations in endogenous natriuretic peptides. NEP, however, cleaves a broad spectrum of substrates, which partially hold significant implications in HFrEF. The effect of NEP-inhibition on these peptides has not been investigated thoroughly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14442DOI Listing

Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.

Pulm Circ 2020 Jul-Sep;10(3):2045894020931317. Epub 2020 Jun 15.

Section of Cardiology, Faculty of Medicine, Lund University, Lund, Sweden; The Hemodynamic Lab, Skåne University Hospital, Lund, Sweden.

Adrenomedullin is a potent vasodilatory peptide, linked to pulmonary arterial hypertension pathology. Proximity extension assays were utilized to study plasma biomarkers related to vasoregulation, with focus on adrenomedullin peptides and precursor levels, collectively referred to as ADM. ADM was measured in 48 treatment-naïve pulmonary arterial hypertension patients at diagnosis, and in 31 of them at an early treatment follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2045894020931317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297127PMC

Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review.

Eur J Heart Fail 2020 Jun 27. Epub 2020 Jun 27.

Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Aim: Diagnosing Heart Failure with Preserved Ejection Fraction (HFpEF) in the non-acute setting remains challenging. Natriuretic peptides have limited value for this purpose, and a multitude of studies investigating novel diagnostic circulating biomarkers have not resulted in their implementation. This review aims to provide an overview of studies investigating novel circulating biomarkers for the diagnosis of HFpEF and determine their risk of bias (ROB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1944DOI Listing

Elevated Angiotensin 1-7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure.

Circ Heart Fail 2020 Jun 25:CIRCHEARTFAILURE120006939. Epub 2020 Jun 25.

Division of Cardiology, Department of Medicine (K.W., R.B., G.Y.O.).

Background: ACE2 (angiotensin-converting enzyme 2) and Ang 1-7 (angiotensin 1-7) are endogenous negative regulators of the renin-angiotensin system exerting cardioprotective effects in models of heart failure. Recombinant human ACE2 markedly increased plasma Ang 1-7 and lowered Ang II levels in phase II clinical trials. We hypothesize that the dynamic state of this renin-angiotensin system protective arm could influence long-term outcomes in patients with heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.006939DOI Listing

Cardiac hypertrophic risk markers of left ventricle and left atrium in chronic heart failure due to aortic and mitral valve disease.

Acta Radiol 2020 Jun 22:284185120933530. Epub 2020 Jun 22.

Faculty of Biological Sciences, Department of Biochemistry, Quaid-I-Azam University, Islamabad, Pakistan.

Background: Chronic valvular heart disease leads to systolic dysfunction and left atrial enlargement that ultimately results in heart failure.

Purpose: To investigate prognostic importance of Echocardiography and plasma natriuretic peptide levels that increase as a compensatory response and can be used as predictive markers for cardiac hypertrophy.

Material And Methods: The patients were divided into three groups: 51 with left ventricle hypertrophy due to aortic valve disease; 126 with left atrial enlargement due to mitral valve dysfunction; and 76 with both conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0284185120933530DOI Listing

The Importance of Natriuretic Peptides in Cardiometabolic Diseases.

J Endocr Soc 2020 Jun 15;4(6):bvaa052. Epub 2020 May 15.

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.

The natriuretic peptide (NP) system is composed of 3 distinct peptides (atrial natriuretic peptide or ANP, B-type natriuretic peptide or BNP, and C-type natriuretic peptide or CNP) and 3 receptors (natriuretic peptide receptor-A or NPR-A or particulate guanynyl cyclase-A natriuretic peptide receptor-B or NPR-B or particulate guanynyl cyclase-B, and natriuretic peptide receptor-C or NPR-C or clearance receptor). ANP and BNP function as defense mechanisms against ventricular stress and the deleterious effects of volume and pressure overload on the heart. Although the role of NPs in cardiovascular homeostasis has been extensively studied and well established, much remains uncertain about the signaling pathways in pathological states like heart failure, a state of impaired natriuretic peptide function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jendso/bvaa052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278279PMC

NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study.

Int J Cardiol Heart Vasc 2020 Aug 5;29:100553. Epub 2020 Jun 5.

Cardiovascular Center, St. Josef Hospital Bochum, Ruhr-University Bochum, Germany.

Background: Beside their role in the diagnosis of heart failure in symptomatic patients with dyspnea, natriuretic peptides have been suggested to improve risk prediction of cardiac events and mortality in asymptomatic cohorts. We aimed to evaluate the prognostic value of NT-proBNP for cardiovascular and all-cause mortality above traditional risk factors in a prospective cohort study of unselected elderly patients in a representative primary care setting.

Methods: We followed 6382 patients of the getABI-study for 7 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcha.2020.100553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280763PMC

[Value of some clinical parameters in predicting continuous renal replacement therapy-related hypotension].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020 Apr;32(4):488-493

Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China. Corresponding author: Cheng Hai, Email:

Objective: To screen the clinical parameters in predicting continuous renal replacement therapy (CRRT)-related hypotension in the patients with renal failure.

Methods: A retrospective analysis was conducted. Patients with renal failure received CRRT admitted to Qingdao Municipal Hospital from July 1st, 2012 to June 30th 2019 were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn121430-20200123-00085DOI Listing

Angiotensin Receptor Neprilysin Inhibitors-2019 Update.

Cardiovasc Drugs Ther 2020 Jun 9. Epub 2020 Jun 9.

Cardiology Department, Medical School, Democritus University of Thrace, Dragana, 68100, Alexandroupolis, Greece.

An abundance of new data regarding the use of the novel drug compound sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the initial publication of the PARADIGM-HF study in 2014. This review summarises the most recent evidence (2019 and onwards) of sacubitril/valsartan in CHF patients as well as provides a critical appraisal of these data. New data are grouped in categories such as real-world data, randomised controlled trials, surrogate end-points, cost-effectiveness, use of sacubitril/valsartan as an anti-hypertensive treatment, effect on diuretic dosing and implementation of this novel compound in other populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07015-8DOI Listing

N-terminal pro-brain natriuretic peptide serum levels reflect attrition of the Fontan circulation.

Cardiol Young 2020 Jun;30(6):753-760

Center for Congenital Heart Diseases, Department of Pediatric Cardiology/Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Objective: N-terminal pro-brain natriuretic peptide has an established role in the diagnosis and prognosis of heart failure. In Fontan patients, this peptide is often increased, but its diagnostic value in this particular non-physiologic, univentricular circulation is unclear. We investigated whether N-terminal pro-brain natriuretic peptide represents ventricular function or other key variables in Fontan patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1047951120000657DOI Listing

Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease.

Clin Biochem 2020 Jun 5. Epub 2020 Jun 5.

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; Centre for Kidney Disease Research, The University of Queensland, Queensland, Australia; Translational Research Institute, Brisbane, Australia. Electronic address:

Natriuretic peptides (NP), especially B type (BNP) and its N-terminal pro-B type natriuretic peptide (NT-proBNP), have long been regarded as biomarkers of volume overload and tools to exclude heart failure in the general population. However, their role in end-stage kidney disease (ESKD) is less certain given that BNP and NT-proBNP are excreted by the kidney and so serum concentrations of NPs are nearly universally elevated compared to controls. Nevertheless, the accumulated evidence suggests thatserum concentrations of NPs in patients with ESKD show moderate or strong positive relationships with underlying heart disease, abnormal cardiac structure or function and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2020.05.013DOI Listing

Single-cell Transcriptome Analysis Indicates New Potential Regulation Mechanism of ACE2 and NPs signaling among heart failure patients infected with SARS-CoV-2.

medRxiv 2020 May 15. Epub 2020 May 15.

Integrative Bioinformatics, ESCBL, NIEHS, National Institutes of Health, Research Triangle Park, NC, 27709, USA.

Background: COVID-19 patients with comorbidities such as hypertension or heart failure (HF) are associated with poor clinical outcomes. Angiotensin-converting enzyme 2 (ACE2), the critical enzyme for SARS-CoV-2 infection, is broadly expressed in many organs including heart. However, the cellular distribution of ACE2 in the human heart, particularly the failing heart is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/2020.04.30.20081257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241106PMC

Inflammation and Circulating Natriuretic Peptide Levels.

Circ Heart Fail 2020 Jun 8:CIRCHEARTFAILURE119006570. Epub 2020 Jun 8.

Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G).

Background: NPs (natriuretic peptides) are cardiac-derived hormones that promote natriuresis, diuresis, and vasodilation. Preclinical evidence suggests that nonhemodynamic triggers for NP release exist, with a few studies implicating inflammatory stimuli. We examined the association between inflammation and NP levels in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006570DOI Listing

Clinical predictors of all-cause mortality in patients presenting to specialist heart failure clinic with raised NT-proBNP and no heart failure.

ESC Heart Fail 2020 Jun 4. Epub 2020 Jun 4.

Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.

Aims: Clinical outcomes for patients suspected of having heart failure (HF) who do not meet the diagnostic criteria of any type of HF by echocardiography remain unknown. The aim of this study was to investigate the clinical predictors of all-cause mortality in patients with suspected HF, a raised N-terminal pro-b-type natriuretic peptide (NTproBNP) and who do not meet the diagnostic criteria of any type of HF by echocardiography.

Methods And Results: Relevant data were taken from the Sheffield HEArt Failure (SHEAF) registry (222349P4). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12742DOI Listing

Cardiovascular Consequences of Acute Kidney Injury.

N Engl J Med 2020 06;382(23):2238-2247

From the Department of Anesthesiology and Perioperative Care, University of California, San Francisco, San Francisco (M.L.); and INSERM 942, Lariboisière Hospital, and French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Paris (M.L.), and Université de Lorraine, INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, INSERM Unité 1116, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, and F-CRIN INI-CRCT, Nancy (P.R.) - all in France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1916393DOI Listing

Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study.

Glob Heart 2020 Mar 25;15(1):25. Epub 2020 Mar 25.

Department of Cardiology, Herlev Gentofte University Hospital, DK.

Objective: This study evaluated the associations between the natriuretic peptide activity and the neurohormonal response in non-obese and obese outpatients with and without heart failure (HF).

Background: Obesity-related HF may be a distinct subtype of HF. Obesity is associated with lower plasma concentrations of natriuretic peptides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5334/gh.776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218759PMC

Impact of Sacubitril-Valsartan on Markers of Glomerular Function.

Curr Heart Fail Rep 2020 Jun 3. Epub 2020 Jun 3.

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600, Genk, Belgium.

Purpose Of Review: To provide pathophysiological and clinical insights into the effects of sacubitril/valsartan on glomerular function.

Recent Findings: Heart failure and glomerular dysfunction are closely intertwined. In addition to reduced heart failure hospitalization and all-cause mortality, patients treated with sacubitril/valsartan have a slower deterioration of glomerular filtration rate over time compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-020-00463-1DOI Listing

A multi-center, randomized, double-blind, placebo-parallel controlled trial for the efficacy and safety of shenfuqiangxin pills in the treatment of chronic heart failure (Heart-Kidney yang deficiency syndrome).

Medicine (Baltimore) 2020 May;99(21):e20271

National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences.

Background: Heart failure (HF) is the final stage of various cardiac diseases with poor prognosis. The integrated traditional Chinese medicine (TCM) and western medicine therapy has been considered as a prospective therapeutic strategy for chronic heart failure (CHF). There have been small clinical trials and experimental studies to demonstrate the efficacy of Shenfu Qiangxin Pills (SFQX) for treating CHF, however, there is still a lack of further high-quality trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249903PMC
May 2020
5.723 Impact Factor

Contentious role of 'Good Adiponectin' in pulmonary and cardiovascular diseases: Is adiponectin directed therapy a boon or a bane?

Biochimie 2020 May 27;175:106-119. Epub 2020 May 27.

Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, India. Electronic address:

After two decades of its discovery, numerous facts of adiponectin (APN) biology has been uncovered, yet, APN remains an elusive adipokine. Findings from clinical studies and animal models established APN's ameliorative role in cardiovascular disease (CVD) and pulmonary disease (PD) but the same condition is prognostic for mortality in the same set of patients which cornered APN towards a dubious state. A repertoire of mechanisms associated with the positive association of APN in both lean/cachectic or obese CVD and PD patients from past publications are evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biochi.2020.05.008DOI Listing

Natriuretic peptides in pleural effusions: Beyond a diagnosis of heart failure.

Authors:
José M Porcel

Respirology 2020 May 25. Epub 2020 May 25.

Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Lleida, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.13847DOI Listing

Sustained heavy drinking over 25 years is associated with increased N-terminal-pro-B-type natriuretic peptides in early old age: Population-based cohort study.

Drug Alcohol Depend 2020 Jul 13;212:108048. Epub 2020 May 13.

Department of Epidemiology and Public Health, University College London, London, WC1E 6BT, UK; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Wort's Causeway, Cambridge, CB1 8RN, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.

Heavy alcohol consumption is associated with an increased risk of heart failure. We sought to investigate whether levels of NT-proBNP differ by alcohol consumption profiles, both current drinking as well as cumulative exposure to drinking over several decades in a general population sample.

Methods: Data on 2054 participants (49% male) were taken from the UK Medical Research Council National Survey for Health and Development, a longitudinal cohort study based on a nationally representative sample of births in 1946. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2020.108048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301434PMC

Cardiac natriuretic peptides.

Nat Rev Cardiol 2020 May 22. Epub 2020 May 22.

Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Investigations into the mixed muscle-secretory phenotype of cardiomyocytes from the atrial appendages of the heart led to the discovery that these cells produce, in a regulated manner, two polypeptide hormones - the natriuretic peptides - referred to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating an endocrine function for the heart. Studies on the gene encoding ANP (NPPA) initiated the field of modern research into gene regulation in the cardiovascular system. Additionally, ANP and BNP were found to be the natural ligands for cell membrane-bound guanylyl cyclase receptors that mediate the effects of natriuretic peptides through the generation of intracellular cGMP, which interacts with specific enzymes and ion channels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41569-020-0381-0DOI Listing

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.

J Am Heart Assoc 2020 Jun 19;9(11):e015071. Epub 2020 May 19.

Department of Internal Medicine II Division of Cardiology Medical University of Vienna Vienna Austria.

Background Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the relationship of circulating neprilysin with neurohumoral activation and the impact of plasma neprilysin activity on prognosis in HFrEF. Methods and Results A total of 369 chronic HFrEF patients were enrolled prospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.015071DOI Listing

Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.

Int Heart J 2020 May 15;61(3):492-502. Epub 2020 May 15.

Division of Cardiology, Nihon University Itabashi Hospital.

Atrial fibrillation (AF) and heart failure (HF) often coexist. The aims of this study were to explore the factors associated with the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the association between prognosis and a history of HF or the serum NT-proBNP level in Japanese patients with AF.The present sub-study was based on the SAKURA AF Registry, a Japanese multicenter observational registry that included 3267 AF patients (median follow-up period: 39 months). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.19-560DOI Listing

Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.

Curr Heart Fail Rep 2020 Jun;17(3):67-76

Department of Internal Medicine Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Purpose Of The Review: The purpose of this review is to describe the effects of angiotensin receptor neprilysin inhibitor (ARNI) therapy on the natriuretic peptide axis (NPA), with a particular focus on B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and C-type natriuretic peptide (CNP) to better understand the biology behind the improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF).

Recent Findings: BNP, ANP, and CNP are the three main natriuretic peptides (NP); they share a common structure and ultimately mediate their actions by activating cyclic guanosine monophosphate (cGMP). ARNI therapy results in a decrease of N-terminal pro-BNP (NT-proBNP) and increase of BNP levels respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-020-00458-yDOI Listing

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.

Eur Heart J 2020 05;41(19):1821-1829

Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Aims: To compare demographic characteristics, clinical presentation, and outcomes of patients with and without concomitant cardiac disease, hospitalized for COVID-19 in Brescia, Lombardy, Italy.

Methods And Results: The study population includes 99 consecutive patients with COVID-19 pneumonia admitted to our hospital between 4 March and 25 March 2020. Fifty-three patients with a history of cardiac disease were compared with 46 without cardiac disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehaa388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239204PMC

Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation.

J Clin Med 2020 May 5;9(5). Epub 2020 May 5.

Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy.

The management of mitral valve regurgitation (MR), a common valve disease, represents a challenge in clinical practice, since the indication for either surgical or percutaneous valve replacement or repair are guided by symptoms and by echocardiographic parameters which are not always feasible. In this complex scenario, the use of natriuretic peptide (NP) levels would serve as an additive diagnostic and prognostic tool. These biomarkers contribute to monitoring the progression of the valve disease, even before the development of hemodynamic consequences in a preclinical stage of myocardial damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9051348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290430PMC

Prognostic value of nt-probnp, and echocardiographic indices of diastolic function, in hospitalized patients with acute heart failure and preserved left ventricular ejection fraction.

Int J Cardiol 2020 May 4. Epub 2020 May 4.

Division of Cardiology, Hospital Italiano de Buenos Aires, Argentina.

Background: Several parameters have proven useful in assessing prognosis in outpatients with heart failure with preserved ejection fraction (HFpEF). In contrast, prognostic determinants in HFpEF hospitalized for an acute event are poorly investìgated.

Aim: To determine the predictive value of NT-proBNP, and diastolic function (assessed by E/e'), in patients with HFpEF hospitalized for acute heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2020.04.044DOI Listing

Tumour biomarkers: association with heart failure outcomes.

J Intern Med 2020 May 5. Epub 2020 May 5.

From the, Department of Cardiology, Uni, University Medical Center Groningen, Groningen, the Netherlands.

Background: There is increasing recognition that heart failure (HF) and cancer are conditions with a number of shared characteristics.

Objectives: To explore the association between tumour biomarkers and HF outcomes.

Methods: In 2,079 patients of BIOSTAT-CHF cohort, we measured six established tumour biomarkers: CA125, CA15-3, CA19-9, CEA, CYFRA 21-1 and AFP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.13053DOI Listing

Recently approved and under investigation drugs for treating patients with heart failure.

Curr Cardiol Rev 2020 Apr 29. Epub 2020 Apr 29.

Department of Pharmacology, Southern Illinois School of Medicine. United States.

Heart failure (HF) represents a leading cause of morbidity and mortality worldwide. Despite the recent advances in the treatment of this condition, patients´ prognosis remains unfavorable in most cases. Sacubitril/valsartan and ivabradine have been recently approved to improve clinical outcomes in patients with HF with reduced ejection fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573403X14666180702151626DOI Listing

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).

ESC Heart Fail 2020 Apr 29. Epub 2020 Apr 29.

Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Aims: Little is known about the impact of sodium glucose co-transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes in N-terminal pro-brain natriuretic peptide (NT-proBNP), in that patient population.

Methods And Results: Patients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting-dose: 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12707DOI Listing

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma.

Endocr Connect 2020 May;9(5):438-444

Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

Aims: Neprilysin degrades natriuretic peptides in circulation and is also suggested to degrade the gut hormones gastrin and cholecystokinin. Neprilysin inhibition has become a therapeutic strategy and thus a regimen in need of further testing in terms of other hormonal axes besides natriuretic peptides. The aim of this study was to examine whether acute inhibition of neprilysin affects meal-induced responses in gastrin and cholecystokinin concentrations in healthy individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-19-0563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274559PMC

[Soluble ST2 - as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure].

Kardiologiia 2019 Nov 6;60(2):111-121. Epub 2019 Nov 6.

Bakulev National Medical Research Center for Cardiovascular Surgery, Ministry of Health of the Russian Federation.

This review focuses on possibilities of using soluble ST2 as a HF marker for diagnostics, stratification of risk of adverse events, and for evaluation of prognosis and treatment effectiveness in patients with CHF. Circulating biomarkers are an essential element of algorithms for diagnostics, stratification of risk, and evaluation of prognosis in patients with HF. The recognized "gold standard", natriuretic peptides, has several well-known limitations, and multiple new candidate biomarkers have appeared in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18087/cardio.2020.2.n816DOI Listing
November 2019

N-Terminal-pro-Brain natriuretic peptide dynamics during effort phenotypes ischemic heart failure and determines prognosis regardless of ejection fraction.

Peptides 2020 Jul 22;129:170315. Epub 2020 Apr 22.

Heart Failure Unit and Cardiopulmonary Laboratory, University Cardiology Department, I.R.C.C.S., Policlinico San Donato University Hospital, Milan, Italy.

Ischemic heart disease leading to heart failure (HF) portends a high overall morbidity and mortality. A higher N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) at rest reflects HF severity and impaired cardiac output, most often secondary to reduced ejection fraction (EF). As an insufficient increase in cardiac output during exertion is common in all HF phenotypes, we examined the value of NT-pro-BNP during exercise testing as a risk stratification index for ischemic HF secondary to either reduced (HFrEF) or mid-ranged/preserved EF (HFmrEF/HFpEF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2020.170315DOI Listing

ARNI in cardiovascular disease - current evidence and future perspectives.

Future Cardiol 2020 Apr 22. Epub 2020 Apr 22.

Department of Cardiology, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin receptor II blocker - neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. This trial has provided a strong evidence base for treatment of HFrEF in various subsets of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2019-0089DOI Listing

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.

ESC Heart Fail 2020 Jun 15;7(3):856-864. Epub 2020 Apr 15.

Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin, Germany.

Aims: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet to be determined. In addition, no prior studies have compared sacubitril/valsartan with angiotensin-converting enzyme inhibitor therapy. We sought to compare the effect of ARNI to background-medication-based individualized comparators (BMICs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP), functional capacity [6 min walk distance (6MWD)], symptoms, and quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ)] in patients with HF and EF >40% in a randomized clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261527PMC

B-type natriuretic peptide levels and diagnostic accuracy: excess fluid volume.

Rev Gaucha Enferm 2020 9;41(spe):e20190095. Epub 2020 Apr 9.

Universidade Federal do Rio Grande do Sul (UFRGS), Escola de Enfermagem. Porto Alegre, Rio Grande do Sul, Brasil.

Aim: To analyze the behavior of B-type natriuretic peptide (BNP) in the presence of defining characteristics (DCs) of the nursing diagnosis Excess fluid volume (00026) in patients hospitalized for acute decompensated heart failure.

Methods: Cohort study of patients admitted with acute decompensated heart failure (September 2015 to September 2016) defined by Boston Criteria. Patients hospitalized for up to 36 h with BNP values ≥ 100 pg/ml were included; BNP values at baseline-final assessment were compared by Wilcoxon test, the number of DCs at baseline-final assessment was compared by paired t-test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1983-1447.2020.20190095DOI Listing

The Science Underlying COVID-19: Implications for the Cardiovascular System.

Circulation 2020 Apr 15. Epub 2020 Apr 15.

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China; Basic Medical School, Wuhan University, Wuhan, China.

Corona Virus Disease 2019 (COVID-19) pandemic has impacted health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with pre-existing cardiovascular (CV) disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of the SARS-CoV-2 virus is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S spike protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047549DOI Listing
April 2020
14.430 Impact Factor

RESECTION OF THE ATRIAL APPENDAGES AND ITS IMPACT IN THE NATRIURETIC HOMEOSTASIS: DEVELOPMENT AND VALIDATION OF AN ANIMAL MODEL IN AN ACADEMIC MEDICAL CENTER.

Rev Invest Clin 2020 ;72(2):103-109

Department of Cardiology, Radboud University Medical Center Nijmegen, The Netherlands.

Background: The left atrial appendage (LAAp) resection is an effective treatment approach to reduce the risk of thromboembolism in patients with atrial fibrillation.

Objective: To study was to study the impact of removing atrial appendages in the production of natriuretic peptides (NPs) in conditions of volume overload and to develop an experimental model of LAAp resection.

Materials And Methods: In a swine model of ischemic heart failure (HF), serum NP levels were measured before (Basal-1A) and after (Basal-1B) a fluid overload. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/RIC.19003132DOI Listing
January 2020

Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction.

Clin Res Cardiol 2020 Apr 6. Epub 2020 Apr 6.

Centre d'Investigations Cliniques 1433, Université de Lorraine, INSERM, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Institut Lorrain du cœur Et des, Vaisseaux Louis Mathieu, 4, rue du Morvan, 54500, Vandoeuvre-Les-Nancy, Nancy, France.

Background: Plasma volume (PV) estimated from Duarte's formula (based on hemoglobin/hematocrit) has been associated with poor prognosis in patients with heart failure (HF). There are, however, limited data regarding the association of estimated PV status (ePVS) derived from hemoglobin/hematocrit with clinical profiles and study outcomes in patients with HF and preserved ejection fraction (HFpEF).

Methods And Results: Patients from North and South America enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT) with available hemoglobin/hematocrit data were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00392-020-01639-4DOI Listing

Specialty-Based Variability in Diagnosing and Managing Heart Failure With Preserved Ejection Fraction.

Mayo Clin Proc 2020 Apr;95(4):669-675

Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. Electronic address:

Objective: To quantify differences in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF) between cardiologists and noncardiologists, who often diagnose and manage HFpEF.

Methods: Cardiologists and noncardiologists (internal medicine, medicine/pediatrics, family medicine, geriatrics) were anonymously surveyed between January 16, 2018, and March 2, 2018, regarding practices related to diagnosing and managing HFpEF at the University of Michigan and Weill Cornell Medical Center. Response data were compared using χ analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2019.09.026DOI Listing

[The Prognostic Role of Biomarkers in Patients With Chronic Heart Failure].

Kardiologiia 2020 Feb 4;60(1):16-22. Epub 2020 Feb 4.

Republican Scientific and Practical Center "Cardiology".

Objective Investigate the role of biomarkers in the prognosis of the clinical course of the disease in patients with chronic heart failure (CHF) of different NYHA functional classes (FC).Material and Methods The study included 132 patients with CHF: Group 1 was composed of 70 patients with NYHA FC II CHF, and Group 2 included 62 patients with FC III-IV CHF. The patients underwent clinical, instrumental, functional, and laboratory measurements, which included serum concentrations of NT-proBNP, ST-2, galectin-3, and C-reactive protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18087/cardio.2020.1.n882DOI Listing
February 2020

Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.

JACC Heart Fail 2020 May 30;8(5):372-381. Epub 2020 Mar 30.

Brigham and Women's Hospital, Division of Cardiovascular, Boston, Massachusetts. Electronic address:

Objectives: The authors sought to evaluate the prognostic significance of baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP), whether NT-proBNP modified the treatment response to sacubitril/valsartan, and the treatment effect of sacubitril/valsartan on NT-proBNP overall and in key subgroups.

Background: Sacubitril/valsartan reduces NT-proBNP in heart failure (HF) with both reduced and preserved ejection fraction (EF), but did not significantly reduce total HF hospitalizations and cardiovascular death compared with valsartan in patients with HF with preserved EF (HFpEF).

Methods: In the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial, 4,796 patients with HFpEF and elevated NT-proBNP were randomized to sacubitril/valsartan or valsartan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchf.2020.03.002DOI Listing

The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind.

JACC Heart Fail 2020 May 30;8(5):382-385. Epub 2020 Mar 30.

Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchf.2020.03.003DOI Listing

Sex-related differences in contemporary biomarkers for heart failure: a review.

Eur J Heart Fail 2020 May 27;22(5):775-788. Epub 2020 Mar 27.

University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands.

The use of circulating biomarkers for heart failure (HF) is engrained in contemporary cardiovascular practice and provides objective information about various pathophysiological pathways associated with HF syndrome. However, biomarker profiles differ considerably among women and men. For instance, in the general population, markers of cardiac stretch (natriuretic peptides) and fibrosis (galectin-3) are higher in women, whereas markers of cardiac injury (cardiac troponins) and inflammation (sST2) are higher in men. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319414PMC

N-terminal Pro-B-Type Natriuretic Peptide and Malnutrition in Patients on Hemodialysis.

Int J Nephrol 2020 5;2020:9528014. Epub 2020 Mar 5.

Service de Cardiologie, Centre Hospitalier Universitaire, Guadeloupe, France.

Natriuretic peptides, brain natriuretic peptide (BNP), and N-terminal probrain natriuretic peptide (NT-proBNP) are mainly known as diagnostic markers for heart failure with high diagnostic and prognostic values in the general population. In patients who are undergoing hemodialysis (HD), changes in NT-proBNP can be related to noncardiac problems such as fluid overload, inflammation, or malnutrition and can also be influenced by the dialysis characteristics. The current review aimed to summarize findings from studies on the association between NT-proBNP and malnutrition in HD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/9528014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077038PMC

Authors' reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension.

Pulm Circ 2020 Jan-Mar;10(1):2045894020910979. Epub 2020 Mar 13.

Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2045894020910979DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074514PMC

Natriuretic peptides for heart failure screening in nursing homes: a systematic review.

Heart Fail Rev 2020 Mar 21. Epub 2020 Mar 21.

Department of Family Medicine, Faculty of Medicine, University of Ljubljana, 56 Poljanski nasip, 1000, Ljubljana, Slovenia.

The high burden of heart failure in nursing-home populations is due to advanced age and comorbidities. Heart failure is often undiagnosed or misdiagnosed in this population and therefore remains untreated. We review the use of natriuretic peptide biomarkers for screening heart failure in nursing-home residents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-020-09944-wDOI Listing

[Peripartum cardiomyopathy: clinical key to diagnosis].

An Sist Sanit Navar 2020 Apr 20;43(1):93-97. Epub 2020 Apr 20.

Medicina Interna. Hospital Universitario Miguel Servet. Zaragoza..

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy that is caused by heart failure secondary to a dysfunction of the left ventricle at the end of pregnancy or in the first months following childbirth. The diagnosis is performed by electrocardiogram, radiography of the thorax and increase of natriuretic peptides. Bedside radiography can contribute with data that help early diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23938/ASSN.0780DOI Listing